Posted on 10/25/2023 7:52:43 PM PDT by ConservativeMind
An international randomized controlled trial has reported that the combination therapy of atezolizumab and bevacizumab in the adjuvant setting is safe and effective in reducing cancer recurrence in patients with the primary liver cancer, hepatocellular carcinoma (HCC), at high risk for recurrence after curative intent resection or ablation.
Liver cancer is the sixth most common cancer. Liver resection or ablation, a process that uses heat to destroy tumors, are potentially curative treatment options for HCC.
Still, 70 to 80% of patients experience cancer recurrence within five years of receiving these treatments. Currently, there is no recognized standard of care for adjuvant therapy in patients with HCC after potentially curative treatment. As a result, clinical outcomes after curative intent liver resection and ablation in HCC are poorer than that of other common cancers which have efficacious adjuvant therapy, such as breast and colorectal cancer.
To address this significant unmet clinical need in HCC, IMbrave050, a global, open-label phase III trial was conducted between 2019 and 2022 to evaluate the safety and efficacy of adjuvant atezolizumab and bevacizumab.
Participants were randomly and equally divided into two groups, with one group receiving atezolizumab and bevacizumab and the other group put under active surveillance, which is the current standard-of-care after surgical resection and ablation.
Participants in the treatment arm received intravenous atezolizumab and bevacizumab every 3 weeks for up to 12 months or 17 cycles.
Trial results were positive at the first analysis and show that cancer recurrence was decreased by one-third at the end of the first year. The risk of disease recurrence or death was 28% lower in the group who received adjuvant atezolizumab plus bevacizumab compared to the group who had undergone active surveillance. The safety profile of the adjuvant therapy was consistent with prior studies of atezolizumab and bevacizumab.
(Excerpt) Read more at medicalxpress.com ...
These reduced liver cancer recurrence by 28%.
.
ping
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.